These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 30963365

  • 21. Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction.
    Sime FB, Lassig-Smith M, Starr T, Stuart J, Pandey S, Parker SL, Wallis SC, Lipman J, Roberts JA.
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358583
    [Abstract] [Full Text] [Related]

  • 22. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M, Havel E, Selke-Krulichova I, Safranek P, Bezouska J, Martinkova J.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [Abstract] [Full Text] [Related]

  • 23. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ, Shankar V, Schlichting C, Kuti JL.
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [Abstract] [Full Text] [Related]

  • 24. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
    Thabit AK, Grupper M, Nicolau DP, Kuti JL.
    J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839
    [Abstract] [Full Text] [Related]

  • 25. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
    Jung B, Mahul M, Breilh D, Legeron R, Signe J, Jean-Pierre H, Uhlemann AC, Molinari N, Jaber S.
    Crit Care Med; 2017 May; 45(5):e470-e478. PubMed ID: 28240688
    [Abstract] [Full Text] [Related]

  • 26. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales.
    Cojutti PG, Pai MP, Tonetti T, Siniscalchi A, Viale P, Pea F.
    Antimicrob Agents Chemother; 2024 Apr 03; 68(4):e0140423. PubMed ID: 38411995
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
    Maarbjerg SF, Thorsted A, Friberg LE, Nielsen EI, Wang M, Schrøder H, Albertsen BK.
    Cancer Rep (Hoboken); 2022 Oct 03; 5(10):e1585. PubMed ID: 34796702
    [Abstract] [Full Text] [Related]

  • 31. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
    Öbrink-Hansen K, Juul RV, Storgaard M, Thomsen MK, Hardlei TF, Brock B, Kreilgaard M, Gjedsted J.
    Antimicrob Agents Chemother; 2015 Nov 03; 59(11):7018-26. PubMed ID: 26349823
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
    Gill CM, Nicolau DP, ERACE-PA Global Study Group.
    Clin Ther; 2023 Jan 03; 45(1):72-77. PubMed ID: 36593150
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
    Delattre IK, Hites M, Laterre PF, Dugernier T, Spapen H, Wallemacq PE, Jacobs F, Taccone FS.
    Int J Antimicrob Agents; 2020 Oct 03; 56(4):106113. PubMed ID: 32721604
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
    Tamme K, Oselin K, Kipper K, Tasa T, Metsvaht T, Karjagin J, Herodes K, Kern H, Starkopf J.
    Acta Anaesthesiol Scand; 2016 Feb 03; 60(2):230-40. PubMed ID: 26830215
    [Abstract] [Full Text] [Related]

  • 39. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.
    Carrié C, Legeron R, Petit L, Ollivier J, Cottenceau V, d'Houdain N, Boyer P, Lafitte M, Xuereb F, Sztark F, Breilh D, Biais M.
    J Crit Care; 2018 Dec 03; 48():66-71. PubMed ID: 30172963
    [Abstract] [Full Text] [Related]

  • 40. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E, Padullés-Zamora A, Maisterra-Santos K, Colom-Codina H, Cobo-Sacristán S.
    Farm Hosp; 2019 Sep 01; 43(5):151-157. PubMed ID: 31469627
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.